File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Separate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: Differences between stone formers and normal control subjects

TitleSeparate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: Differences between stone formers and normal control subjects
Authors
Issue Date1993
PublisherPortland Press Ltd. The Journal's web site is located at http://www.clinsci.org/
Citation
Clinical Science, 1993, v. 85 n. 1, p. 33-39 How to Cite?
AbstractUrinary glycosaminoglycans were recovered from the papain digest of polyanions precipitated sequentially by cetylpyridinium chloride and sodium acetate-saturated ethanol. Those from the early morning urine of 48 stone formers and 43 normal control subjects measured 11 and 16 μg of uronic acid/ml of urine, respectively. Preparative agarose gel electrophoresis of the recovered glycosaminoglycans in barium acetate buffer (pH 5.8) yielded fractions containing purely chondroitin sulphate, co-polymeric chondroitin/dermatan sulphates and heparan sulphate. Identification was based on the susceptibility of the fractions to chondroitinase or nitrous acid treatment. Similar compositions of glycosaminoglycan classes were observed in samples from stone formers and normal control subjects. The fractionated glycosaminoglycans were dissolved in urine ultrafiltrate to assay for nucleation-promoting and growth-inhibiting activities towards crystallization of urinary calcium oxalate. When compared at the same uronic acid concentration, both the urinary chondroitin sulphate isomers and heparan sulphates of stone formers demonstrated the capacity to enhance crystal nucleation from calcium oxalate endogenous in urine ultrafiltrates, whereas only urinary heparan sulphates of normal control subjects demonstrated this capacity. Tissue-derived reference chondroitin sulphate, dermatan sulphate and heparin, when similarly tested, showed negligible crystal nucleation-promoting activity. The tissue-derived heparan sulphate was similar to the urinary heparan sulphates in showing marked crystal nucleation-promoting activity. Crystal-growth inhibitory activity was evident in all urinary glycosaminoglycan fractions studied. In particular, urinary heparan sulphate of normal control subjects showed higher activity than that of stone formers or the chondroitin sulphate isomers of both stone formers and normal control subjects (P < 0.005).
Persistent Identifierhttp://hdl.handle.net/10722/147377
ISSN
2015 Impact Factor: 4.996
2015 SCImago Journal Rankings: 2.427
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShum, DKYen_US
dc.contributor.authorGohel, MDIen_US
dc.date.accessioned2012-05-29T06:03:16Z-
dc.date.available2012-05-29T06:03:16Z-
dc.date.issued1993en_US
dc.identifier.citationClinical Science, 1993, v. 85 n. 1, p. 33-39en_US
dc.identifier.issn0143-5221en_US
dc.identifier.urihttp://hdl.handle.net/10722/147377-
dc.description.abstractUrinary glycosaminoglycans were recovered from the papain digest of polyanions precipitated sequentially by cetylpyridinium chloride and sodium acetate-saturated ethanol. Those from the early morning urine of 48 stone formers and 43 normal control subjects measured 11 and 16 μg of uronic acid/ml of urine, respectively. Preparative agarose gel electrophoresis of the recovered glycosaminoglycans in barium acetate buffer (pH 5.8) yielded fractions containing purely chondroitin sulphate, co-polymeric chondroitin/dermatan sulphates and heparan sulphate. Identification was based on the susceptibility of the fractions to chondroitinase or nitrous acid treatment. Similar compositions of glycosaminoglycan classes were observed in samples from stone formers and normal control subjects. The fractionated glycosaminoglycans were dissolved in urine ultrafiltrate to assay for nucleation-promoting and growth-inhibiting activities towards crystallization of urinary calcium oxalate. When compared at the same uronic acid concentration, both the urinary chondroitin sulphate isomers and heparan sulphates of stone formers demonstrated the capacity to enhance crystal nucleation from calcium oxalate endogenous in urine ultrafiltrates, whereas only urinary heparan sulphates of normal control subjects demonstrated this capacity. Tissue-derived reference chondroitin sulphate, dermatan sulphate and heparin, when similarly tested, showed negligible crystal nucleation-promoting activity. The tissue-derived heparan sulphate was similar to the urinary heparan sulphates in showing marked crystal nucleation-promoting activity. Crystal-growth inhibitory activity was evident in all urinary glycosaminoglycan fractions studied. In particular, urinary heparan sulphate of normal control subjects showed higher activity than that of stone formers or the chondroitin sulphate isomers of both stone formers and normal control subjects (P < 0.005).en_US
dc.languageengen_US
dc.publisherPortland Press Ltd. The Journal's web site is located at http://www.clinsci.org/en_US
dc.relation.ispartofClinical Scienceen_US
dc.subject.meshAdulten_US
dc.subject.meshCalcium Oxalate - Urineen_US
dc.subject.meshChondroitin Sulfates - Urineen_US
dc.subject.meshCrystallizationen_US
dc.subject.meshElectrophoresis, Agar Gelen_US
dc.subject.meshElectrophoresis, Cellulose Acetateen_US
dc.subject.meshHeparitin Sulfate - Urineen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshUrinary Calculi - Urineen_US
dc.titleSeparate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: Differences between stone formers and normal control subjectsen_US
dc.typeArticleen_US
dc.identifier.emailShum, DKY:shumdkhk@hkucc.hku.hken_US
dc.identifier.authorityShum, DKY=rp00321en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8149691-
dc.identifier.scopuseid_2-s2.0-0027199113en_US
dc.identifier.volume85en_US
dc.identifier.issue1en_US
dc.identifier.spage33en_US
dc.identifier.epage39en_US
dc.identifier.isiWOS:A1993LN39000006-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridShum, DKY=7004824447en_US
dc.identifier.scopusauthoridGohel, MDI=7004532182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats